Bilayer Tablet Formulation Weight Ratio Optimization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diabetes treatments, particularly for type II diabetes, face challenges in effectively managing blood glucose levels without causing weight gain and maintaining the potency and uniformity of bilayer tablet formulations, especially due to differences in weight ratios between metformin and SGLT2 inhibitor layers, leading to issues like cracking and cross-contamination.

Innovation Solution

The development of bilayer tablet formulations comprising metformin extended release (XR) as the first layer and an SGLT2 inhibitor as the second layer, with specific excipients like sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, and magnesium stearate, and optionally a film coating, to enhance stability and uniformity, reducing weight differentials and improving compactability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bilayer tablet formulations are prepared with metformin and SGLT2 inhibitor layers, then blood glucose control effectiveness is improved, but weight gain side effect occurs and manufacturing uniformity deteriorates due to weight ratio differences

Engineering Contradiction:

Improveblood glucose control effectivenessVSAvoidtablet formulation uniformity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent modifies the weight ratio parameters of the bilayer tablet formulation, specifically setting the metformin layer to weigh approximately 85-95% and the SGLT2 inhibitor layer to weigh approximately 5-15%. This parameter adjustment resolves the manufacturing uniformity issue while preserving the therapeutic effectiveness of both components.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If bilayer tablet formulations are prepared with metformin and SGLT2 inhibitor layers, then blood glucose control effectiveness is improved, but cracking and cross-contamination occur during manufacturing

Engineering Contradiction:

Improveblood glucose control effectivenessVSAvoidtablet manufacturing processability

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent optimizes the weight distribution parameters between layers (metformin layer: 85-95%, SGLT2 inhibitor layer: 5-15%) and adjusts excipient ratios to improve compactability. These parameter changes prevent cracking and cross-contamination during tablet manufacturing while maintaining the dual-drug therapeutic effect.

Inventive Principle:

Principle #35Parameter changes

3Manufacturing precision

If weight differentials between layers are reduced, then manufacturing uniformity and compactability are improved, but tablet mass reduction may occur

Engineering Contradiction:

Improvetablet formulation uniformityVSAvoidtablet mass

Core Design Contradiction:

Manufacturing precisionVSQuantity of substance

Solution Approach 1:

The patent carefully balances the weight ratio parameters to achieve optimal compactability and uniformity without compromising the total tablet mass. The metformin layer (85-95%) and SGLT2 inhibitor layer (5-15%) are formulated with appropriate excipients to maintain sufficient tablet mass for effective drug delivery while ensuring manufacturing precision.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP3315124B1Bilayer tablet formulations

Publication Date: 2021.01.06 ASTRAZENECA AB

AI summary

The present invention relates to bilayer tablets comprising a metformin hydrochloride formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention further relates to medical uses of said bilayer tablets and to pharmaceutical combinations comprising said bilayer tablets.